Cogent Biosciences Excellent NEWS Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. The Company’s primary focusses target different forms of mastocytosis and gastrointestinal stomal tumors (GIST). The firm’s positive data from Phase 3 PEAK Trial has been studied with the combination of its drug bezuclastinib with Sunitinib. Many analysts . . . This content is for paid subscribers. Please click here to …
Aspen Neuroscience Aspen Neuroscience, Inc. – a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen’s lead program, ANPD001, for moderate to advanced Parkinson’s disease. The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from …
Novo Nordisk in the NEWS On Monday, November 17, 2025, Novo Nordisk (NVO) announced that Wegovy® (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic® are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026. This introductory offer is good for the first two months of therapy and . . . This content is for paid subscribers. Please click here …
Vertex Pharmaceuticals in the NEWS On November 8, 2025, Vertex Pharmaceuticals Incorporated (VRTX) announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the . . . This content is for paid …
Cogent Biosciences On November 10, 2025, Cogent Biosciences (COGT) reported positive data from its Phase 3 PEAK trial of bezuclastinib plus sunitinib in patients with imatinib-resistant or intolerant Gastrointestinal Stromal Tumors (GIST). The combination reached a median progression free survival (mPFS) of 16.5 months compared to sunitinib monotherapy, which reached a mPFS of 9.2 months. The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Ionis Pharmaceuticals On November 8, 2025, Ionis Pharmaceuticals (IONS) announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The . . . This content is for …
Cidara Therapeutics Q3 Financial Results SAN DIEGO, November 06, 2025, Cidara Therapeutics, Inc. (CDTX) reported financial results for the third quarter ended September 30, 2025, and provided recent business updates. From Cidara Therapeutics Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, said, “With our Phase 3 ANCHOR study now over 50 percent enrolled, we expect to achieve target enrollment . . . This …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
